Ethylene

Ethylene

SCHEMBL4673777

C=C.N#Cc1cccc(C2(O)CCC(=O)CC2)c1

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.40
CNR2 P34972 1/20 0.38
GRIN2B Q13224 1/20 0.38
GSK3B P49841 1/20 0.38
MEN1 O00255 1/20 0.38
CYP2C9 P11712 1/20 0.38
KMT2A Q03164 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
OPRL1 P41146 1/20 0.37
PKLR P30613 1/20 0.37
BACE1 P56817 1/20 0.37
NSD2 O96028 1/20 0.37
VNN1 O95497 2/20 0.36
CCR2 P41597 1/20 0.36
KCNH2 Q12809 1/20 0.36
CNR1 P21554 1/20 0.36
ABCC9 O60706 1/20 0.36
ABCC8 Q09428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612068 0.97 HSD11B1 (0.42) HSD11B1CNR2GRIN2BGSK3BMEN1
SCHEMBL2270824 0.78 DRD2 (0.46) HSD11B1CNR2GRIN2BGSK3BOPRM1
SCHEMBL744125 0.78 OPRM1 (0.49) HSD11B1GRIN2BMEN1CYP2C9KMT2A
SCHEMBL11796632 0.76 KCNA3 (0.48) HSD11B1MEN1CYP2C9KMT2AOPRM1
SCHEMBL614816 0.76 MEN1 (0.35) MEN1CYP2C9KMT2AOPRM1OPRD1
SCHEMBL21077929 0.75 CNR2 (0.44) HSD11B1CNR2GRIN2BOPRM1OPRD1
SCHEMBL17888200 0.75 KMT2A (0.45) CNR2KMT2AOPRM1OPRD1OPRK1
SCHEMBL612783 0.74 MEN1 (0.44) MEN1CYP2C9KMT2AOPRM1OPRD1
SCHEMBL5387141 0.74 PKLR (0.48) HSD11B1CNR2GRIN2BCYP2C9OPRM1
Ethylene SCHEMBL4679206 0.74 MCHR1 (0.39) HSD11B1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453501-B1 N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY SCHERING CORP (US) 2008-08-13 EP disclosed
US-7348328-B2 MCH antagonists for the treatment of obesity SCHERING CORPORATION (US) 2008-03-25 US disclosed
EP-1453501-A1 N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY SCHERING CORPORATION (US) 2004-09-08 EP disclosed
US-20040122017-A1 MCH antagonists for the treatment of obesity SCHERING CORPORATION 2004-06-24 US disclosed
WO-2003047568-A1 N-ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY SCHERING CORPORATION (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122017-A1 MCH antagonists for the treatment of obesity MCHR1, MCHR2, MC4R HSD11B1 1009/4885CNR2 210/4885GRIN2B 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.